Fluid Pharma is a technology-driven pharmaceutical company focused on transforming the way medicines are formulated and experienced. We apply our proprietary MicroCoat® technology to develop innovative, user-centric oral dosage forms that are palatable, safe, and easy to take – transforming the way people and animals experience treatment.
Fluid Pharma is a technology-driven pharmaceutical company focused on transforming the way medicines are formulated and experienced. We apply our proprietary MicroCoat® technology to develop innovative, user-centric oral dosage forms that are palatable, safe, and easy to take – transforming the way people and animals experience treatment.
The company’s first marketed product, Tat-Fit™, emerged after winning a CRACK IT Challenge from the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) — successfully developing taste-masked tamoxifen micro-pellets for oral dosing in mice used in transgenic research.
Fluid Pharma has also advanced the development of a child-friendly artesunate/amodiaquine combination therapy for malaria treatment, supported by Unitaid and is now listed among the World Health Organisation (WHO) Paediatric Drug Optimisation (PADO) priorities.
Fluid Pharma’s strategic growth and innovation continue by expanding its product pipeline in human and pet medicines – forging partnerships with leading industrial and academic collaborators to deliver the next generation of user-friendly treatments.
Fluid Pharma’s versatile platform enables the development of novel formulations and the repurposing of existing APIs, offering broad potential for partnerships and commercialization. We collaborate with contract manufacturers (CMOs) to scale production and work with industry partners through co-development and out-licensing to accelerate market access.
Fang earned a PhD in Pharmaceutics from University College London, School of Pharmacy, where her doctoral research led to the patented DuoCoat® technology (Evonik) — later used in the commercialisation of ASACOL™ 1600 mg (mesalazine), a once-daily tablet for the treatment of ulcerative colitis. This early success inspired her passion for translating scientific innovation into practical, patient-focused medicines.
Following her PhD, she held an academic position at the University of Hertfordshire, focusing on developing dosage forms designed to make medicines easier to take — particularly for children and adults with swallowing difficulties. Her research culminated in the invention of MicroCoat™, a scalable, industrially adaptable micro-pellet coating technology for taste masking and controlled release. Fang founded Fluid Pharma to bring MicroCoat® to commercial reality.
After obtaining a Masters degree and Doctorate in Chemistry from the University of Nottingham, Pete spent almost 10 years in the chemical industry working for a Nottingham spinout company which focused on the production of high-quality nanomaterials. Subsequently, Pete moved into the Higher Education sector as Head of Innovation at the University of Hertfordshire in 2018. Now as Director of the recently formed Research and Enterprise Services department, Pete oversees all research grant award activity as well as Herts’ business-facing innovation offering. Pete also oversees UH’s IP portfolio and supports UH spinout Fluid Pharma through advising the board and providing support services aligned with the University’s offering and its wider network.
Suzanne is a highly experienced healthcare and innovation consultant, specialising in supporting health tech businesses in developing successful route-to-market strategies. With over three decades in the life sciences and healthcare sectors, including with GSK and Roche, Suzanne brings a unique blend of strategic, regulatory, and commercial insight. Throughout her career, she has championed patient experience and now acts as a patient advocate with government organisations and across the voluntary sector as well working as a Royal Society Entrepreneur in Residence and business consultant. Her experience is grounded in a deep understanding of health innovation ecosystems, with a strong track record of translating scientific research into viable commercial solutions.
Alan holds a BSc in Pharmaceutical Sciences and is currently pursuing his Master’s degree at the University of Hertfordshire. He has been a valued member of Fluid Pharma for over four years, contributing his strong technical expertise in formulation development, manufacturing, and quality control. Throughout his time at Fluid Pharma, Alan has played a key role in multiple projects, collaborating with industry partners and academic institutions across the UK and internationally.
